P97-PROTEIININ MERKITYS BORRELIOOSISSA

[Bb]

Lähettäjä: Soijuv Lähetetty: 21.12.2004 9:47

Seuraavissa artikkeleissa mainitaan rautaa sitovan proteiinin p97 olevan yhteydessä Alzheimerin tautiin. Potilaiden aivojen rautapitoisuus on koholla. Kyseinen proteiini mainitaan myös borrelia bakteerinkohdalla. En ole tutkinut asiaa enempää - onko kenelläkään enempää tietoa asiasta? Raudan yhteys borrelioosiin esiintyy kuitenkin artikkeleissa aina silloin tällöin. (Aihe liittyy lähinnä mikrobiologien erikoisalaan.)


J Med Microbiol. 1992 Mar;36(3):209-14.


Identification of an endoflagellar associated protein in Borrelia burgdorferi.

Eiffert H, Schlott T, Hoppert M, Lotter H, Thomssen R.

Department of Medical Microbiology, University of Gottingen, Germany.

DNA of Borrelia burgdorferi was cleaved by the endonuclease EcoRI and ligated with the bacteriophage expression vector lambda gt11. After infection of the Escherichia coli strain Y1089, the plaques of recombinant phages were screened with a B. burgdorferi antiserum (human) for fusion proteins containing borrelia antigen.s A positive clone produced a hybrid protein (p200) of c. 200 Kda. The corresponding native borrelia protein (p97) was identified as having an Mr of 97 Kda. To localise protein p97 in the B. burgdorferi cell, immunoelectronmicroscopy and a Western blot of isolated flagella were used. Antibodies directed against proteins p200 and p97 recognised epitopes associated with the flagella.

PMID: 1372363 [PubMed - indexed for MEDLINE]

-------------------

Blood protein could lead to Alzeimer's Test

By Gloria Chang, October 30, 1996

A blood protein that is elevated in people with Alzheimer's may lead to a simple blood test to diagnose the disease before the symptoms appear.

In a study published in the November issue of Nature Medicine magazine, researcher Dr. Wilfred A Jefferies at the University of British Columbia Biotechnology Laboratory reports that the iron binding protein p97 is higher in people with Alzheimer's disease (AD).

"Our findings have linked the iron-binding protein p97 to the development of AD," writes Jefferies.

Jefferies and colleagues, Malcolm Kennard and Dr. Howard Feldman of the university and Dr. Tatsuo Yamada of Chiba University in Japan, compared blood levels of p97 in 27 Canadians with probable Alzheimer's and 25 without it. They also compared blood levels in eight Japanese people with probable Alzheimer's and seven with other neurological diseases. Alzheimer's patients showed consistently higher p97 levels.

The findings are preliminary but could be useful in coming up with a diagnostic test to determine Alzheimer's and in testing potential therapy for the disease. Alzheimer's is a neurodegenerative disease that affects cognition, behavior and function. Experts say brain deterioration in Alzheimer's patients begins 20 to 40 years before symptoms appear and suggest if treatments could be started in this early period, it might delay symptoms. Right now, Alzheimer's can be definitively diagnosed only with an autopsy, although there are other indicators that may suggest a person has the disease.

"Early diagnosis would give families more time to plan for the proper care of Alzheimer's patients and could eliminate the diagnosis of AD for conditions that mimic its symptoms, such as depression or stroke," writes Jefferies.

According to the Canadian Study of Health and Aging published in 1994, there were 161,000 Canadians over the age of 65 diagnosed with Alzheimer's in 1991. That number is expected to more than double by 2031 to 387,000 with an aging population.


---------------------


J Alzheimers Dis. 2001 Jun;3(3):339-344.

Assessing p97 as an Alzheimer's disease serum biomarker.

Jefferies WA, Dickstein DL, Ujiie M.

Biotechnology Laboratory and the Biomedical Research Centre, Departments of Medical Genetics, Microbiology and Immunology and Zoology, University of British Columbia, Canada.

The search is ongoing for a reliable serum biomarker for AD. The level of iron is elevated in the brain of Alzheimer's disease (AD) patients. Our studies have demonstrated that the level of the iron transport protein, p97, is increased in the serum of AD patients but not in various control groups. These results have recently been confirmed by another laboratory who extended our findings by demonstrating that p97 is not elevated in other neurodegenerative diseases. This qualifies p97 as a potentially powerful biomarker for AD. Although the relationship between increased level of iron and p97 in the AD brain is not well understood, our research supports the hypothesis that p97 over-expressed by senile plaque associated reactive microglia is exocytosed and appears in blood. The relationship between elevated levels of serum p97 and AD, together with the possible future clinical application of p97 are considered in this report.

PMID: 12214055 [PubMed - as supplied by publisher]




Nat Med. 1996 Nov;2(11):1230-5.
Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease.

Kennard ML, Feldman H, Yamada T, Jefferies WA.

Biotechnology Laboratory, University of British Columbia, Vancouver, Canada.

Alzheimer's disease is a progressive and incurable disease whose prevalence increases dramatically with age. A biochemical marker for monitoring the onset and progression of the disease would be a valuable tool for disease management. In addition, such a marker might be used as an end point in clinical intervention protocols. Here we provide evidence that the soluble form of the iron binding protein p97 is found in elevated amounts in the serum of Alzheimer's patients compared with healthy controls. This biochemical marker has the potential for identifying subjects afflicted with the disease and possibly for monitoring the onset and longitudinal progression of the disease.

PMID: 8898750 [PubMed - indexed for MEDLINE]

-------------------------
Life Sci. 2004 Oct 8;75(21):2539-49. Links

Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin--the antioxidant proteins.

Chauhan A, Chauhan V, Brown WT, Cohen I.

NYS Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, New York 10314, USA.

Autism is a neurological disorder of childhood with poorly understood etiology and pathology. We compared lipid peroxidation status in the plasma of children with autism, and their developmentally normal non-autistic siblings by quantifying the levels of malonyldialdehyde, an end product of fatty acid oxidation. Lipid peroxidation was found to be elevated in autism indicating that oxidative stress is increased in this disease. Levels of major antioxidant proteins namely, transferrin (iron-binding protein) and ceruloplasmin (copper-binding protein) in the serum, were significantly reduced in autistic children as compared to their developmentally normal non-autistic siblings. A striking correlation was observed between reduced levels of these proteins and loss of previously acquired language skills in children with autism. These results indicate altered regulation of transferrin and ceruloplasmin in autistic children who lose acquired language skills. It is suggested that such changes may lead to abnormal iron and copper metabolism in autism, and that increased oxidative stress may have pathological role in autism.

PMID: 15363659 [PubMed - indexed for MEDLINE]

---------------------------------

[PDF] Association study of a promoter polymorphism of UFD1L gene with ...
File Format: PDF/Adobe Acrobat
... with Npl4 a binary binding complex for p97, a protein ... to a 55% increase of UFD1L
protein in human ... disorders, including schizophrenia and autism [Margolis et ...
doi.wiley.com/10.1002/ajmg.1489 -
[ More results from doi.wiley.com ]